Skip to main content
S&P 5007,650.50+0.17%DOW51,682.64-0.18%NASDAQ26,522.54+0.39%BTC$81,273.00+6.27%ETH$2,618.91+7.14%GOLD$4,415.90+0.37%OIL$95.47-1.81%
Smart Investors Daily
AR

NASDAQ · ARTV

Artiva Biotherapeutics, Inc.

Healthcare · Biotechnology

$8.61

Up+$0.17 (+2.01%)

Updated Sep 19, 2026, 7:26 PM

SID Score

5.1/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
142.85M
P/E ratio
-1.97
Dividend yield
0.00%
52-week range
$4.74 – $14.53
Volume
2.21M
Avg. volume
1.03M

Price performance

ARTV price history

1M range · 20 trading sessions · Daily adjusted prices

ARTV closed at $8.61 after 20 trading sessions, down 21.23% for the selected period.

Last close
$8.61
Period change
-21.23%
Period low
$8.44
Period high
$11.94
Daily close
View OHLC price history
ARTV OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Sep 18, 2026$8.45$8.75$8.40$8.612.21M
Sep 17, 2026$8.66$8.72$8.35$8.44456.52K
Sep 16, 2026$8.89$9.03$8.485$8.60516.99K
Sep 15, 2026$10.05$10.05$8.84$8.91584.58K
Sep 14, 2026$10.21$10.55$10.13$10.14243.87K
Sep 11, 2026$10.49$10.61$10.10$10.22228.44K
Sep 10, 2026$10.70$10.93$10.36$10.42449.48K
Sep 9, 2026$10.78$11.15$10.73$10.79325.34K
Sep 8, 2026$10.83$11.16$10.70$10.88211.7K
Sep 4, 2026$11.02$11.34$10.94$11.19168.59K
Sep 3, 2026$11.34$11.35$10.98$11.125365.62K
Sep 2, 2026$11.26$11.5071$11.05$11.31306.52K
Sep 1, 2026$11.00$11.355$10.88$11.28268.86K
Aug 31, 2026$11.01$11.35$10.88$11.30249.84K
Aug 28, 2026$11.78$11.80$11.00$11.09223.49K
Aug 27, 2026$11.72$12.08$11.56$11.94218.27K
Aug 26, 2026$11.75$11.93$11.60$11.77262.56K
Aug 25, 2026$11.60$11.91$11.53$11.77266.36K
Aug 24, 2026$10.83$11.70$10.49$11.52307.24K
Aug 21, 2026$11.26$11.5995$10.7601$10.93199.42K

Latest ARTV news

The latest Smart Investors Daily articles mentioning ARTV.

Stock researchCompany · Overview

ARTV research

Overview

Company profile and research snapshot.

Company profile

Artiva Biotherapeutics Inc is a biopharmaceutical company. The company is engaged in advancing a pipeline of off-the-shelf, allogeneic NK cell therapies for the treatment of hematologic malignancies or solid tumors. The pipeline program of the company includes Artiva-Funded Trials and Collaborator-Funded Trials. The company pipeline includes AlloNK: is an allogeneic, off-the-shelf, cryopreserved NK cell therapy candidate designed to enhance the antibody-dependent cellular cytotoxicity (ADCC) effect of mAbs to drive B-cell. Others products includes: CAR-NK(AB201),CAR-NK(AB205).

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Buy
Average target
$20.50
Implied upside
—
Analysts
12
ARTV recent ratings
DateFirmRatingTarget
Jun 8, 2026NeedhamBuy—
May 12, 2026NeedhamBuy—
May 11, 2026Cantor FitzgeraldOverweight—
May 11, 2026WedbushOutperform—
May 8, 2026HC Wainwright & Co.Buy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 17, 2026

Artiva Biotherapeutics to Participate in the Stifel 2026 Virtual Immunology and Inflammation Forum

SAN DIEGO, Sept. 17, 2026 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV) (Artiva), a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell therapies for patients with debilitating autoimmune diseases, today announced that management will participate in a fireside chat at the Stifel 2026 Virtual Immunology and Inflammation Forum on Thursday, September 24, 2026, at 10:00 am EDT. To access the audio webcast and subsequent archived reco

Yahoo · Sep 8, 2026

Artiva Biotherapeutics Provides Update on Planned AlloNK® Data Disclosures and Development Milestones for the Remainder of 2026

Updated clinical data expected in the second half of 2026 from at least 20 patients with refractory rheumatoid arthritis (RA) treated with AlloNK and rituximab in the ongoing company-sponsored Phase 2a basket trial, each with at least six months of follow-up, including at least 10 patients who would meet key eligibility criteria for the Phase 3 registrational trial in refractory RA Updated clinical data expected in the second half of 2026 from at least 10 patients with Sjögren disease (SjD) and

Yahoo · Sep 2, 2026

Artiva Biotherapeutics to Participate in Upcoming Investor Conferences in September

SAN DIEGO, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV) (Artiva), a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell therapies for patients with debilitating autoimmune diseases, today announced that management will participate at the following investor conferences: 2026 Cantor Global Healthcare Conference – live fireside chat on Wednesday, September 9, 2026 at 10:20 am EDTH.C. Wainwright 28th Annual Global Inv

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By